Onconetix Registers 100M Share Resale — Potential 2,282% Dilution Now Tradable
ONCO sits 50% above its 52-week low of $0.587 on elevated volume (1.9× avg).
Summary
Onconetix's 424B3 makes 100 million shares held by Seven Knots LLC freely tradable, representing potential dilution of 2,282% of shares outstanding. The Nasdaq Exchange Cap currently limits conversion to 789,426 shares pending stockholder approval.
Key Events · Financing and Capital Events · ONCO
-
100M Share Resale Registration Effective
The 424B3 prospectus registers 100,000,000 shares for resale by Seven Knots LLC, issuable upon conversion of Series F Preferred Stock at an initial conversion price of $0.9767 per share.
-
Potential Dilution of 2,282%
If all 100,000,000 shares were issued, they would represent 2,282% of the 4,380,522 shares outstanding as of August 28, 2026 — a share count more than twenty times the current float.
-
Nasdaq Exchange Cap Limits Immediate Conversion
Due to Nasdaq Listing Rule 5635(d) and the 4.99% beneficial ownership blocker, the company currently can only issue 789,426 shares upon conversion. Stockholder approval is required to remove the cap.
-
Going Concern and Cash Runway Pressure
The prospectus reiterates substantial doubt about the company's ability to continue as a going concern, with cash of approximately $5.1 million as of August 28, 2026 — insufficient to fund operations for one year.
Analysis · ONCO · Life Sciences
The prospectus makes the 100 million shares held by Seven Knots LLC freely tradable, quantifying the overhang at 2,282% of the current 4.38 million shares outstanding. While the Nasdaq Exchange Cap currently limits immediate conversion to 789,426 shares, the filing confirms the company intends to seek stockholder approval to remove that cap. Against a backdrop of a going-concern warning, $5.1 million in cash, and a pending Realbotix reverse-merger, this registration arms a single holder with the ability to sell a share count more than twenty times the existing float — a structural overhang that will weigh on the stock until resolved.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCO was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.59 to $209.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.